Menopause Hormone Therapy (HRT) in Woodbridge, NJ

Bioidentical hormones in Woodbridge: what it means

"Bioidentical" describes a hormone whose chemical structure matches one the body makes. Estradiol and micronized progesterone are both bioidentical: their structure matches the hormones the ovaries make. FDA-approved versions of both are sold by prescription at retail pharmacies.

Only 2 OB-GYNs list a primary practice address in Woodbridge in the NPI registry. For 20,086 residents that is 10.0 per 100,000, under the US 17.8 and below New Jersey's 19.9. That is about 1,500 women aged 45 to 64 for each OB-GYN in the city, a ratio rather than a count of open appointments.

Counting the area around it, 214 OB-GYNs practice in Woodbridge or within 10 miles and 2,524 within 25 miles: 26.0 for every 100,000 of the 9,694,262 people who live within 25 miles, a dense supply. Whether or not you have an OB-GYN, you can ask a physician licensed in New Jersey about menopause hormone therapy online from Woodbridge, with no waiting room.

"BHRT" often means compounded hormones, a cream, a blend such as Bi-Est or a pellet that a pharmacy mixes for one prescription. They are not FDA-approved, which means the FDA cannot assure their safety or effectiveness. The FDA also says it has no evidence that they are safe and effective, or more effective than approved hormone therapy. A 2020 National Academies review found no rigorous evidence of their safety and effectiveness.

For women in Woodbridge, a physician licensed in New Jersey can prescribe estradiol (pill, patch, cream or vaginal) and progesterone when they fit your history. There are no pellets. Because the dispensing pharmacy also compounds, you can ask whether your estradiol or progesterone is an FDA-approved product. Two options are compounded for certain: testosterone cream for women and Bi-Est are not FDA-approved.

BHRT pellet clinics work differently: they place a hormone pellet under the skin in the office, and compounded pellets are not FDA-approved. The Endocrine Society points to a study that found hormone levels well above the expected range in women using them. ACOG's guidance is to prefer FDA-approved menopause hormone therapy to compounded hormones.

Sources: FDA: Menopause · FDA: National Academies study of compounded bioidentical hormones (2020) · Endocrine Society position statement on compounded bioidentical hormones (2019) · ACOG Clinical Consensus No. 6, compounded bioidentical menopausal hormone therapy (2023) · CMS NPPES NPI full file, 2026-10-11